Abstract  by unknown
JACC February1997 ABSTRACTS-Poster 49A
associated CHD risk factors (RF) in asymptomatic siblings of persons with
documented premature CHD (<60 years of age). Using the JNCVguidelines,
fJ09siblings (52% male, 17%African American) were classified into treatment
cstegorfes. The prevalence of HTN (2140/90 mmHg, defined by an average
of three resting measures using AHA guidelines) was 38%: half of these
hypertensive siblings met criteria for nonpharmacologic intervention, and the
other half for drug treatment. Among those requiring treatment according
to JNC V, only 56Y0 were aware that they had HTN. This is extremely
important, given the high prevalence of other CHD RF among those eligible
for treatment: 73% were hypercholesterolemic (LDL ? 130 mg/dl); 59% were
obese, aooording to NCHS atandards; 27% were current smokers; and 85%
were consuming more than 30% of calories from fat. Of those eligible for
drug treatment, only 41% were on antihyperfensives, the majority of which
were diuretics. These findings indicate a markedly high prevalence of HTN
wmbined with iow awareness and treatment levels, which particularly in
the presence of mdtlphRF, demonstrate the need for moreaggressive
screening and treatment in this high-risk population.
El952154 Hyperinsullnemia,OverweightandHighBloodPressureIn YoungAdults-The RiodeJaneiro
Study
R. Pozzen, S.L.D. Silva, A.A. BrandFro,A.P. Brandao. L)eptot
Cardiology-StateUniversityof RiodeJaneiro,13rasil
We analyzed the relationship of hyperinsulinemia and overweight in young
adufts (17-23 Yrs) with different percentiles of blood pressure. We evaluata
3906 children and adolescents (10-15 yrs) In their schools in ordar to deter-
mine blood pressure (BP) cuwes. 64 individuals out of these population were
accompanied throughout 8 years in four consecutive screening and stratified
in 3 groups according to the tracking of BP: Group 1 (n = 23, 12 malas) with
BP ? 95th percentile in at least 3 out of 4 evaluations; Group 2 (n = 28, 13
males) with BPs 50’0 percentile Inat least 3 out of 4 screenings and Group 3
(n= 13,3 males) without stable BP percentile. All 64 subjects were submitted
to an oral glucose tolerance test with 75 g of dextrosol, after 12 hours fasting.
Blood samples were collected at O, 30, 60, 90 and 120 minutes for insulin
and glucose measurements. Ovenveight was defined as a body mass index
(BMI) z 25 k@m2:BI ? 30 &lU/ml was considered abnormal, peak value
of insulin (PVI) and gkrmse (PVG) were defined as the highest value after
stimulus and WHO’s criteriou$ were used to identify individuals with glucose
Intolerance (Gl). BMI, systolic (SBP) and diastolic blood pressure (DBP)
were also used for comparison and correlation among the groups. The main
results were: 1) There were no age or sex differences among the groups (p >
0.05); 2) Group 1 had greaterBMl(66.8+2.8x 80.8& 1.5 x 59.3 +2.4 p <
0.02), SBP (128.3+ 2.3 x 109.9 + 1.6 x 115.5+ 1.7p < 0.0001) and DBP
(78.6 & 1.5 x 64.9 + 1.6 x 71.8 + 2.4p < 0.0001) than the other groups;
3) Group 1 had graater BI (17.1 + 2.8 x 8.8 + 0.9 x 10.3 + 1.6p < 0.02),
BG (90.9 + 2.3 X 81.6& 1.6 X 81.6 + 2.2p < 0.0005), PVI (153.4& 76.1
x 96.9 + 33.3 x 123.2 + 54.9 p < 0.005) and PVG (141.3 + 21.0 x 121.1
+ 23.2 x 120.0 + 28.2 p < 0.005) than the other groups; 4) Group 1 had
more prevalence of overweight (6.7% x 32.0% O%p < 0.05) and abnormal
values of BI (3.6% x 21.7% x OYOp < 0.05) than the other groups; 5) GI wee
more prevalent in group 1 than in group 2 (13.I’Yo x O%p < 0.05); 6) The
multivariated analysis showed that SBP was significantly correlated with all
insuiin variables, even when BMI was statistically controlled. We concluded
that the association of high blood pressure, high insulin and glucose levels
and body size can be detected early, but the meaning of these findings would
be better explained on longitudinal studies.
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M.G. Franzosi, A.P. Maggioni, E. Santoro, G. Tognoni for the GISSI-3
Investigators. ktituto MarioNegri,Italy
As cost containment of the health care system has become a priority, clinical
trialsare now more likely to measure cost-effectiveness outcome as well as
medical outcome. GISSI-3 study tested an early (within 24 hours) treatment
of ACE-inhibitor (Iisinopril) for42 days in 19,394 relatively unselected patients
with acute myocardlal infarction. A statistically significant reduction of 6 week
mortality was achieved in Iisinopril allocated patients when compared to
nolisinopril allocated patients [7.5 (SD 3.8) lives saved per 1,000 treated
patients].
We performed a cost-effectiveness analysis in the total population admit-
tedto GISS1-3study,usingdetaontheuseof medical resourcas prospectively
collected during hospitalization. Charges were converted to costs. Effective-
nesswasmeasured in terms of number of additional survivors among patients
assigned to Iisinopril group. Cost-effectiveness ratios were expressed as cost
per premature death avoided.
On the basis of the 6-week survival analysis of GISS,I-3study, the com-
parative cost-effectiveness ratio iorthe use of Iisinopril was 2,300 US dollars
per premature death avoided.
A sensitivity analysis was conducted to examine the effects of varying the
estimated absolute reduction in monality of 7.5 lives saved per 1000 treated
patients) throughout itsconfidence interval (95% Cl: 0.4 to 14,6 lives saved
per 1,000 treated patients). The cost-effectiveness ratios consequently could
vary from 43,300 to 1,2C0US dollars per premature death avoided.
The cost-effectiveness of Iisinopril treatment compares very favorably
with that of other interventions for acute myocardlal infarction,
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The existence of gender bias in the delivery of cardiac care remains con-
troversial, but if it exists, it may occur at the earliest point in the diagnostic
sequence. We reporf herein the results of the first population-based study
examining sex differences in evaluation and outcome after the first emer-
gency room (ER) visit for chest pain (CP). Between 1985 and 1992, 691
Olmsted County residents (433 men, 258 women), were seen in the ER for
CP.Except forage (women older), men and women were similar in baseline
characteristics, type of CP or ECG findings. Adjustment for baseline charac-
teristics and risk sfatus (AHCPR unstable angina guidelines) was pertormed
with multivariate analysis for the 2 endpoints: utilization of procedures and
outcome. The percentages of men and women having procedures within 90
days after ER visit were:
Men Women pvalue*
?3 procedures 17,20/. 11.6”A <0.01
Any Cardiac Diagnostic 81% 65”A <0.005
AnyCardiacTherapeutic 23,6% 14.s% <0.005
Any GI Diagnostic 12% 15.8°A NS
*p valuesareadjustedforfactorsrelatedto proceduraluse.
After a median follow-up of 4.9 years, 200 cardiovascular events (my-
ocardial infarcti, heart failure, cardiac arrest, cardiac death, and stroke)
were recorded. After adjustment, female sex was not associated with time to
first event.
These population-based data indicate that, affera first ERvisit for CP: (1)
utilization of procedures is lower in women (2) despite this, women do not
appear at increased risk for cardiovascular events.
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Previous studies have demonstrated that a small minority of employees uti-
Iizethe majorityof corporate health costs, which can be reduced by improving
overall risk status. In a pilot work-site project study of 164 participants and
161 nonparticipants, we aee$ssed the effects of a comprehensive risk as-
sessment and modification program (RAMP) on overall outpatient, inpatient,
and total (inpatient, outpatient, emergency room, and pharmacy) annualized
medical costs before and after a 6 month intervention program. At baseline,
42 (26%) were classified as “high-risk” by anthropometric measurements,
lipids, smoking and blood pressure status, as well as overall health habits
and behavioral data. Following RAMP, high-risk patients markedly improved
their overall health risk score by 40% (p c 0,01), 57?&of whom achieved
low-risk status, Furthermore, low-risk participants improved thair mean total
health score by 10% (p < 0.001). Following RAMP,outpatient medical costs
fell by 35% (p c 0.01) in participants compared to a 16% increase (p <
0.05) in nonparticipants (p <0.01 between groups). In addition, inpatient
costs fell by 73% (p < 0.001) in participants compared with 60% (p < 0.001)
in nonparticipants, resulting in a total reduction in medical costs of 48%
